Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021

Freedman, Mark S.; Ault, Kevin A.; Bernstein, Henry H.

doi:10.15585/mmwr.mm7006a2

Cited by 25 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intramuscular influenza vaccines are available as trivalent vaccines containing two strains of influenza A and one strain of influenza B, and quadrivalent vaccines, which contain an additional B strain. 12 13 Two quadrivalent vaccines are currently recommended for adults age ≥65-a high-dose quadrivalent vaccine (Fluzone High-Dose) and an adjuvanted quadrivalent vaccine (Fluad Quadrivalent). 12 13 The live attenuated intranasal influenza vaccine is contraindicated in patients taking biologics or other immunomodulatory therapies (eg, JAK inhibitors).…”

Section: Influenza Vaccination Backgroundmentioning

confidence: 99%

“…12 13 Two quadrivalent vaccines are currently recommended for adults age ≥65-a high-dose quadrivalent vaccine (Fluzone High-Dose) and an adjuvanted quadrivalent vaccine (Fluad Quadrivalent). 12 13 The live attenuated intranasal influenza vaccine is contraindicated in patients taking biologics or other immunomodulatory therapies (eg, JAK inhibitors). Influenza vaccine efficacy is estimated using a surrogate of haemagglutinin inhibition titres.…”

Section: Influenza Vaccination Backgroundmentioning

confidence: 99%

“…40 41 High-dose influenza vaccines may be more effective in patients with rheumatic disease, [42][43][44] although at this time the high-dose vaccine is recommended only for adults aged ≥65. 12 A randomised study of 279 patients with RA found that those receiving the high-dose influenza vaccine were more likely to seroconvert (OR: 2.99, 95% CI: 1.46 to 6.11); this effect was similar in patients on synthetic and biologic DMARDs. 42 Rituximab-treated patients should ideally receive the influenza vaccine before initiating rituximab, or as long after the last dose of rituximab and 2-4 weeks before the next dose, 41 as compatible with the influenza season.…”

Section: Recommendationsmentioning

confidence: 99%

“…The first retrospective review of 403 patients with rheumatic disease vaccinated with the RZV found a 7% incidence of disease flare within 12 weeks of receiving a vaccine dose; this incidence was considered to be similar to expected rates from clinical trials. 66 However, a second retrospective review of 359 patients with rheumatic diseases found that 16% had a flare of their disease within 12 on September 12, 2021 by guest. Protected by copyright.…”

Section: Safety In Patients With Rheumatic Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

2021

View full text Add to dashboard Cite

Patients with rheumatic diseases are at increased risk of infectious complications; vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs may reduce the immunogenicity of common vaccines. We will review here available data regarding the effect of these medications on influenza, pneumococcal, herpes zoster, SARS-CoV-2, hepatitis B, human papilloma virus and yellow fever vaccines. Rituximab has the most substantial impact on vaccine immunogenicity, which is most profound when vaccinations are given at shorter intervals after rituximab dosing. Methotrexate has less substantial effect but appears to adversely impact most vaccine immunogenicity. Abatacept likely decrease vaccine immunogenicity, although these studies are limited by the lack of adequate control groups. Janus kinase and tumour necrosis factor inhibitors decrease absolute antibody titres for many vaccines, but do not seem to significantly impact the proportions of patients achieving seroprotection. Other biologics (interleukin-6R (IL-6R), IL-12/IL-23 and IL-17 inhibitors) have little observed impact on vaccine immunogenicity. Data regarding the effect of these medications on the SARS-CoV-2 vaccine immunogenicity are just now emerging, and early glimpses appear similar to our experience with other vaccines. In this review, we summarise the most recent data regarding vaccine response and efficacy in this setting, particularly in light of current vaccination recommendations for immunocompromised patients.

show abstract

Section: Influenza Vaccination Backgroundmentioning

confidence: 99%

Section: Influenza Vaccination Backgroundmentioning

confidence: 99%

Section: Recommendationsmentioning

confidence: 99%

Section: Safety In Patients With Rheumatic Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

2021

View full text Add to dashboard Cite

show abstract

“…The most successful vaccines to date have been developed by Moderna, Pfizer/BioNTech and Johnson & Johnson. Both Moderna and the Pfizer/BioNTech vaccines are designed novel mRNA and lipid nanoparticle (LNP)-based vaccines that have been approved for adult use in the U.S. in late 2020 [23][24][25]. Until February 2021, there was no treatment or vaccine available to prevent or treat COVID-19 [13,14].…”

Section: Introductionmentioning

confidence: 99%

Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement

et al. 2021

View full text Add to dashboard Cite

COVID-19 is a devastating respiratory and inflammatory illness caused by a new coronavirus that is rapidly spreading throughout the human population. Over the past 12 months, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has already infected over 160 million (>20% located in United States) and killed more than 3.3 million people around the world (>20% deaths in USA). As we face one of the most challenging times in our recent history, there is an urgent need to identify drug candidates that can attack SARS-CoV-2 on multiple fronts. We have therefore initiated a computational dynamics drug pipeline using molecular modeling, structure simulation, docking and machine learning models to predict the inhibitory activity of several million compounds against two essential SARS-CoV-2 viral proteins and their host protein interactors—S/Ace2, Tmprss2, Cathepsins L and K, and Mpro—to prevent binding, membrane fusion and replication of the virus, respectively. All together, we generated an ensemble of structural conformations that increase high-quality docking outcomes to screen over >6 million compounds including all FDA-approved drugs, drugs under clinical trial (>3000) and an additional >30 million selected chemotypes from fragment libraries. Our results yielded an initial set of 350 high-value compounds from both new and FDA-approved compounds that can now be tested experimentally in appropriate biological model systems. We anticipate that our results will initiate screening campaigns and accelerate the discovery of COVID-19 treatments.

show abstract

Screening/Physical Exam/Health Maintenance

Conigliaro

Kapoor

2022

Handbook of Outpatient Medicine

View full text Add to dashboard Cite

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021

Cited by 25 publications

References 10 publications

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement

Screening/Physical Exam/Health Maintenance

Contact Info

Product

Resources

About